INNMF
Amplia Therapeutics Limited
OTC Markets OTCQBUSDEQUITY
DELAYED
Last price
0.11
▲ 0.00 (1.90%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.10
Prev close
0.11
Day high
0.11
Day low
0.11
Volume
10.00K
Market cap
—
P/E (TTM)
—
52W range
0.05 – 0.27
Day trading desk
Gap from prior close
0.00%
Prior close 0.10
VWAP
—
—
Relative volume
—
—
Session range
1.90%
0.10 – 0.11
Position in range
100%
Near session high
ATR (14D)
0.01
13.62% of price
Prior day high
0.10
PDH
Prior day low
0.10
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.73%
-1.4%
1M
-2.73%
-6.5%
3M
+8.08%
+5.0%
6M
+78.33%
+67.3%
YTD
+35.44%
+23.2%
1Y
-14.40%
-34.4%
3Y
+114.00%
+39.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on INNMF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Research & development | $9.08M | $7.53M | $5.80M | $4.69M | +20.6% |
| Selling, general & admin | $3.62M | $2.75M | $2.69M | $2.41M | +31.7% |
| Total operating expense | $13.18M | $10.58M | $9.02M | $7.48M | +24.6% |
| Operating income | -$13.18M | -$10.58M | -$9.02M | -$7.48M | -24.6% |
| Net interest income | $681.73K | $219.95K | $66.62K | $43.41K | +209.9% |
| Pre-tax income | -$7.71M | -$6.57M | -$4.50M | -$6.24M | -17.3% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$7.71M | -$6.57M | -$4.50M | -$6.24M | -17.3% |
| Net income to common | -$7.71M | -$6.57M | -$4.50M | -$6.24M | -17.3% |
| Basic EPS | -0.02 | -0.02 | -0.02 | -0.03 | +23.4% |
| Diluted EPS | -0.02 | -0.02 | -0.02 | -0.03 | +23.4% |
| EBIT | -$7.69M | -$6.52M | -$4.42M | -$6.19M | -18.0% |
| EBITDA | -$7.60M | -$6.43M | -$4.34M | -$6.12M | -18.1% |
| Basic shares | 469.65M | 307.21M | 203.67M | 203.63M | +52.9% |
| Diluted shares | 469.65M | 307.21M | 203.67M | 203.63M | +52.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.85M | $10.86M | $3.39M | $9.26M | — | +156.4% |
| Cash & short-term investments | $27.85M | $10.86M | $3.39M | $9.26M | — | +156.4% |
| Total current assets | $33.04M | $14.93M | $6.75M | $10.51M | — | +121.3% |
| Property, plant & equipment | $353.95K | $17.36K | $100.92K | $184.84K | — | +1,938.4% |
| Goodwill & intangibles | $7.94M | $7.94M | $7.94M | $7.94M | — | 0.0% |
| Total assets | $41.44M | $22.94M | $14.85M | $18.68M | — | +80.7% |
| Total current liabilities | $1.67M | $1.89M | $3.40M | $2.75M | — | -11.5% |
| Current debt | — | — | $1.49M | $2.11M | — | — |
| Long-term debt | — | — | — | — | $2.10M | — |
| Total debt | $341.11K | $13.89K | $1.59M | $2.28M | — | +2,355.3% |
| Total liabilities | $1.97M | $1.91M | $3.43M | $2.85M | — | +3.0% |
| Retained earnings | -$152.83M | -$145.54M | -$139.01M | -$134.72M | — | -5.0% |
| Shareholder equity | $39.47M | $21.02M | $11.42M | $15.84M | — | +87.7% |
| Working capital | $31.37M | $13.04M | $3.35M | $7.76M | — | +140.6% |
| Net tangible assets | $31.53M | $13.09M | $3.48M | $7.90M | — | +141.0% |
| Shares issued | 513.07M | 387.95M | 203.67M | 203.67M | — | +32.3% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Capital expenditure | -$33.30K | -$2.07K | -$2.23K | -$17.63K | — | -1,507.2% |
| Investing cash flow | -$96.22K | -$2.07K | -$2.23K | -$58.42K | — | -4,543.7% |
| Share buybacks | -$1.86M | -$1.33M | — | — | -$1.18M | -39.7% |
| Financing cash flow | $25.94M | $14.32M | -$772.98K | -$84.22K | — | +81.1% |
| Free cash flow | -$8.77M | -$6.89M | -$5.13M | -$5.31M | — | -27.3% |
| End cash position | $27.85M | $10.86M | $3.39M | $9.26M | — | +156.4% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-03-31 | 2025-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $27.85M | $10.86M | +156.4% |
| Cash & short-term investments | $27.85M | $10.86M | +156.4% |
| Total current assets | $33.04M | $14.93M | +121.3% |
| Property, plant & equipment | $353.95K | $17.36K | +1,938.4% |
| Goodwill & intangibles | $7.94M | $7.94M | 0.0% |
| Total assets | $41.44M | $22.94M | +80.7% |
| Total current liabilities | $1.67M | $1.89M | -11.5% |
| Total debt | $341.11K | $13.89K | +2,355.3% |
| Total liabilities | $1.97M | $1.91M | +3.0% |
| Retained earnings | -$152.83M | -$145.54M | -5.0% |
| Shareholder equity | $39.47M | $21.02M | +87.7% |
| Working capital | $31.37M | $13.04M | +140.6% |
| Net tangible assets | $31.53M | $13.09M | +141.0% |
| Shares issued | 513.07M | 387.95M | +32.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.11
+1.23% from price
SMA 20
0.10
+4.90% from price
SMA 50
0.10
+9.72% from price
SMA 100
0.11
-0.20% from price
SMA 200
0.10
+7.12% from price
EMA 12
0.11
+1.40% from price
EMA 26
0.10
+4.06% from price
EMA 50
0.10
+5.26% from price
RSI (14)
52.5
Neutral
MACD (12,26,9)
0.00
Hist 0.00
ATR (14)
0.01
13.62% of price
Realised vol 30D
285.7%
Annualised
Bollinger upper
0.12
20, 2σ
Bollinger lower
0.08
20, 2σ
50 / 200 cross
Death
0.10 vs 0.10
Trend bias
Above 200
+7.12%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.49
More volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
285.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-71.6%
Peak to trough
Max drawdown 5Y
-85.1%
Peak to trough
ATR 14
0.01
13.62% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals
Simply Wall St. · 5d ago
Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
Simply Wall St. · 15d ago
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
GlobeNewswire · 19d ago
Amplia Therapeutics partners with Lilly on lung cancer combination trial
Proactive · 19d ago
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
GlobeNewswire · 23d ago
Amplia Announces Publication of New FAK Inhibitor Patent Application
GlobeNewswire · 45d ago
Amplia Announces Appointment of Brett Carter to Board
GlobeNewswire · 47d ago
Amplia Announces Changes to Board’s Leadership Roles
GlobeNewswire · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.